Medical products: local manufacturing opportunities depend on quality systems and dependable demand

Production capacity is only part of the proposition

The prospect of manufacturing medicines or medical devices locally can attract interest from governments, investors and healthcare purchasers. Yet a factory announcement does not establish a sustainable business. A viable supplier must combine the ability to produce with appropriate quality controls, dependable inputs, regulatory readiness and customers able to purchase its output. This article considers the commercial operating model; product-specific medical and regulatory decisions require qualified expertise and current local review.

WHO's work on technology transfer facilitation addresses support for local production of priority health products and technologies. That provides context for the opportunities discussed here. The author's assessment is that businesses should evaluate the entire production and service chain before assuming that localisation will reduce cost or improve availability. The comparison depends on the product, expected volume, technical capability and the reliability of both imported and domestic inputs.

Choose a product and a purchaser segment

A generic pharmaceutical, a diagnostic consumable and a durable medical device have very different production economics. The business should define the product specification, intended purchaser and service requirements with precision. Hospitals may buy through a procurement process, distributors may require inventory support and public agencies may work to a separate contracting timetable. Each route affects how quickly a prospective order can become delivered and paid revenue.

Evidence of demand should include current purchasing volumes, stock availability concerns and the buyer's acceptance criteria. Expressions of support for local industry are useful context but should not be counted as purchase commitments. Early discussions need to establish whether customers will evaluate a new supplier, what documentation they require and how long that evaluation may take.

Quality capability must be built into the investment

Testing, traceability, controlled documentation and staff training require resources before routine output begins. A financial model that treats them as later additions understates the investment needed to operate responsibly. Supplier qualification and changes to materials also need disciplined handling because an apparently minor substitution may affect the product or the evidence supporting it.

Technology transfer should specify what knowledge is being transferred, who provides training and what continuing assistance is available. Access to equipment or a design is not necessarily enough to operate a reliable process. Contracts need appropriate technical and legal review, including the rights required for production and distribution. Businesses should avoid suggesting that international cooperation bypasses these requirements.

Market sizing should account for qualification and utilisation

Begin with verified purchaser demand for a defined product and then consider the portion accessible to a new supplier. Adjust for customer qualification, existing contracts, distribution reach and production capacity. A national healthcare spending figure is much broader than the obtainable market for one manufacturing line. It may be useful background, but it should not be used as the revenue base without a careful bridge to actual units sold.

An illustrative model can test how delayed customer qualification affects cash needs. If a production line becomes operational before purchasers complete evaluation, inventory and staffing costs begin while sales remain uncertain. Vary the qualification period, usable yield and payment delay independently. These are scenario assumptions, not reported industry averages. Their purpose is to identify which uncertainties require evidence before capital is committed.

Distribution and service complete the offering

Customers need a supplier that can deliver the right product consistently and resolve problems responsibly. For durable devices, installation, maintenance, replacement parts and user training may be central to the purchasing decision. For consumables, storage conditions, batch information and replenishment reliability may matter more. The commercial team must understand which commitments the operating organisation can actually meet.

• Maintain a traceable connection between purchased inputs, production batches and deliveries.
• Record purchaser requirements before promising substitutions or alternative specifications.
• Include technical support and maintenance obligations in product profitability reviews.
• Keep escalation routes clear when a quality concern is raised by a customer.

BRICS partnerships should be evaluated on execution

Relationships among manufacturers, research organisations and distributors across BRICS markets can broaden technical and commercial options. Their value depends on specific contributions: process expertise, reliable components, local distribution or support capacity. A broad memorandum is less useful than a clear account of deliverables, responsibilities and the evidence needed for acceptance.

Country differences remain material. A company considering sales in Brazil, India or South Africa needs current advice about the relevant product pathway and commercial obligations. Distribution partners should be assessed for their actual coverage and support capabilities rather than their claimed access to an entire region. The business must also consider how currency movements and shipping delays affect supplies that remain imported.

A dashboard for disciplined expansion

Management should connect sales qualification, production readiness, batch release, service obligations and collections. This reveals whether the growth constraint is market access, process reliability or working capital. The useful milestone is a repeat order fulfilled to the customer's requirements, supported by a stable operating process. Expansion becomes more credible when the company can demonstrate that performance across several cycles rather than relying on the apparent size of unmet healthcare demand.